Complete Durable Response From Carboplatin and Olaparib in a Heavily Pretreated Triple-Negative Metastatic Breast Cancer With Germline BRCA2 and "BRCAness" Mutations.
Publication
, Journal Article
Hong, S; Funchain, P; Haddad, A; Crowe, J; Dalpiaz, N; Abraham, J
Published in: J Oncol Pract
March 2016
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
J Oncol Pract
DOI
EISSN
1935-469X
Publication Date
March 2016
Volume
12
Issue
3
Start / End Page
270 / 272
Location
United States
Related Subject Headings
- Triple Negative Breast Neoplasms
- Treatment Outcome
- Piperazines
- Phthalazines
- Oncology & Carcinogenesis
- Middle Aged
- Humans
- Germ-Line Mutation
- Female
- Carboplatin
Citation
APA
Chicago
ICMJE
MLA
NLM
Hong, S., Funchain, P., Haddad, A., Crowe, J., Dalpiaz, N., & Abraham, J. (2016). Complete Durable Response From Carboplatin and Olaparib in a Heavily Pretreated Triple-Negative Metastatic Breast Cancer With Germline BRCA2 and "BRCAness" Mutations. J Oncol Pract, 12(3), 270–272. https://doi.org/10.1200/JOP.2016.010710
Hong, Sanghee, Pauline Funchain, Abdo Haddad, Joseph Crowe, Nancy Dalpiaz, and Jame Abraham. “Complete Durable Response From Carboplatin and Olaparib in a Heavily Pretreated Triple-Negative Metastatic Breast Cancer With Germline BRCA2 and "BRCAness" Mutations.” J Oncol Pract 12, no. 3 (March 2016): 270–72. https://doi.org/10.1200/JOP.2016.010710.
Hong S, Funchain P, Haddad A, Crowe J, Dalpiaz N, Abraham J. Complete Durable Response From Carboplatin and Olaparib in a Heavily Pretreated Triple-Negative Metastatic Breast Cancer With Germline BRCA2 and "BRCAness" Mutations. J Oncol Pract. 2016 Mar;12(3):270–2.
Hong, Sanghee, et al. “Complete Durable Response From Carboplatin and Olaparib in a Heavily Pretreated Triple-Negative Metastatic Breast Cancer With Germline BRCA2 and "BRCAness" Mutations.” J Oncol Pract, vol. 12, no. 3, Mar. 2016, pp. 270–72. Pubmed, doi:10.1200/JOP.2016.010710.
Hong S, Funchain P, Haddad A, Crowe J, Dalpiaz N, Abraham J. Complete Durable Response From Carboplatin and Olaparib in a Heavily Pretreated Triple-Negative Metastatic Breast Cancer With Germline BRCA2 and "BRCAness" Mutations. J Oncol Pract. 2016 Mar;12(3):270–272.
Published In
J Oncol Pract
DOI
EISSN
1935-469X
Publication Date
March 2016
Volume
12
Issue
3
Start / End Page
270 / 272
Location
United States
Related Subject Headings
- Triple Negative Breast Neoplasms
- Treatment Outcome
- Piperazines
- Phthalazines
- Oncology & Carcinogenesis
- Middle Aged
- Humans
- Germ-Line Mutation
- Female
- Carboplatin